CDBT logo

China Dasheng Biotechnology Company (CDBT) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

China Dasheng Biotechnology Company (CDBT) opera en el sector Financial Services, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 38/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 38/100

China Dasheng Biotechnology Company (CDBT) Perfil de Servicios Financieros

CEOGang Chen
Empleados689
Sede CentralLanzhou, CN
Año de la oferta pública inicial (OPI)2008

China Dasheng Biotechnology Company, operating within the financial services sector as a shell company, focuses on the production and distribution of bacteria-based additives for livestock feed and crop cultivation in China. The company offers biological bacterium blends and preservatives, serving agricultural and livestock markets.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

China Dasheng Biotechnology Company's investment thesis hinges on its niche market in bacteria-based agricultural additives within China. With a negative P/E ratio of -7.14, the company's profitability is a concern. Key value drivers include expanding its product line and increasing market penetration in the agricultural sector. Growth catalysts involve leveraging its existing distribution network and capitalizing on the demand for sustainable agricultural practices. However, potential risks include the company's OTC listing, which implies lower liquidity and higher volatility, as reflected by its beta of 2.26. Further, the absence of dividends may deter income-seeking investors.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Operates in the financial services sector as a shell company.
  • Specializes in bacteria-based products for livestock feed and crop cultivation.
  • Based in Lanzhou, China, serving the People's Republic of China market.
  • P/E ratio of -7.14 indicates current lack of profitability.
  • Beta of 2.26 suggests high volatility compared to the market.

Competidores y Pares

Fortalezas

  • Specialized in bacteria-based agricultural additives.
  • Established presence in the Chinese market.
  • Offers a range of products for both crop and livestock applications.
  • Engages in real estate investment for diversification.

Debilidades

  • Negative P/E ratio indicates lack of profitability.
  • OTC listing suggests higher risk and lower liquidity.
  • Limited geographic diversification outside of China.
  • Dependence on the agricultural sector, which can be cyclical.

Catalizadores

  • Upcoming: Potential expansion into new geographic markets within China.
  • Upcoming: Development and launch of new bacteria-based product lines.
  • Ongoing: Increasing demand for sustainable agricultural practices.
  • Ongoing: Growing awareness of soil health and the benefits of biological additives.

Riesgos

  • Potential: Limited financial disclosure due to OTC listing.
  • Potential: Lower liquidity and higher price volatility.
  • Ongoing: Competition from established agricultural companies.
  • Potential: Changes in agricultural regulations and policies.
  • Ongoing: Dependence on the agricultural sector, which can be cyclical.

Oportunidades de crecimiento

  • Expansion into organic farming markets: The growing demand for organic produce presents an opportunity for China Dasheng Biotechnology Company to tailor its products for organic farming practices. The global organic food market is projected to reach $323.1 billion by 2024, offering a substantial market for specialized bacteria-based additives. This expansion could involve developing certifications and formulations that meet organic standards, enhancing market access and brand reputation.
  • Development of specialized livestock feed additives: Focusing on developing specialized additives for specific livestock needs, such as poultry or swine, can create a competitive advantage. The global animal feed additives market is projected to reach $27.9 billion by 2027. Tailoring products to address specific nutritional deficiencies or health concerns in livestock can increase product value and customer loyalty.
  • Geographic expansion within China: Expanding distribution networks to reach underserved regions within China can significantly increase market penetration. China's agricultural sector is vast and diverse, with varying needs across different provinces. Establishing partnerships with local distributors and agricultural cooperatives can facilitate market entry and build brand awareness in new regions. This targeted approach can capitalize on regional agricultural strengths and address specific local needs.
  • Research and development of novel bacterial strains: Investing in research and development to discover and commercialize novel bacterial strains with enhanced efficacy can drive product innovation. The agricultural biotechnology sector is constantly evolving, with new discoveries leading to improved crop yields and disease resistance. Developing proprietary bacterial strains can create a competitive edge and protect market share through patents and intellectual property.
  • Strategic partnerships with agricultural technology companies: Collaborating with agricultural technology companies to integrate bacteria-based additives into broader agricultural solutions can enhance market reach and product value. This could involve partnerships with companies specializing in precision farming, data analytics, or irrigation systems. Integrating biological additives into these technologies can create synergistic benefits and provide comprehensive solutions for farmers.

Oportunidades

  • Expansion into organic farming markets.
  • Development of specialized livestock feed additives.
  • Geographic expansion within China.
  • Strategic partnerships with agricultural technology companies.

Amenazas

  • Competition from established agricultural companies.
  • Changes in agricultural regulations and policies.
  • Economic downturns affecting the agricultural sector.
  • Potential for product liability claims.

Ventajas competitivas

  • Proprietary bacteria strains and formulations.
  • Established distribution network within China.
  • Specialized knowledge in bacteria-based agricultural additives.
  • Brand recognition in the Chinese agricultural market.

Acerca de CDBT

China Dasheng Biotechnology Company, formerly known as Max Nutrition, Inc., changed its name in March 2008 and is based in Lanzhou, China. The company, along with its subsidiaries, produces, markets, and distributes bacteria-based products used as additives for livestock feed and crop cultivation within the People's Republic of China. Their product line includes artificial microorganisms (AM) and high-efficiency microorganism (HM) based biological bacterium blends, as well as biological preservatives. These products are designed to enhance soil quality, improve nutrient absorption, and reduce diseases in both crops and livestock. Specifically, the company provides AM/HM bacteria-based additives for crops, incorporating components like Bulgaria lactobacillus and beer microzyme. For livestock, the additives soften feed, restrain pathogenic bacteria, and supply beneficial nutrients. Additionally, China Dasheng Biotechnology Company offers FGW bacterial-based preservatives, used for preserving animal specimens and maintaining the freshness of agricultural produce. They also provide bacteria-based fertilizer for plants. The company also engages in residential and commercial real estate investment.

Qué hacen

  • Produces bacteria-based additives for livestock feed.
  • Manufactures bacteria-based additives for crop cultivation.
  • Offers artificial microorganism (AM) based products.
  • Provides high-efficiency microorganism (HM) based products.
  • Distributes biological bacterium blends.
  • Supplies biological preservatives.
  • Engages in residential and commercial real estate investment.

Modelo de Negocio

  • Sells bacteria-based additives directly to farmers and agricultural businesses.
  • Distributes products through a network of distributors and retailers.
  • Generates revenue from the sale of biological preservatives.
  • Derives income from real estate investments.

Contexto de la Industria

China Dasheng Biotechnology Company operates within the agricultural biotechnology sector, which is influenced by trends towards sustainable farming and increasing demand for higher crop yields. The competitive landscape includes companies offering similar biological additives and fertilizers. The market is driven by the need for environmentally friendly solutions and the growing awareness of soil health. China's agricultural sector is a significant market, but competition is intense with both domestic and international players vying for market share.

Clientes Clave

  • Farmers cultivating various crops.
  • Livestock producers raising animals for meat and dairy.
  • Agricultural businesses involved in crop and livestock production.
  • Scientific research institutions requiring animal specimen preservation.
  • Real estate tenants (residential and commercial).
Confianza de la IA: 69% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de China Dasheng Biotechnology Company (CDBT): Price data unavailable

Últimas noticias

No hay noticias recientes disponibles para CDBT.

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para CDBT.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para CDBT.

MoonshotScore

38/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de CDBT en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Gang Chen

CEO

Gang Chen is the CEO of China Dasheng Biotechnology Company, leading a team of 689 employees. Information on his detailed career history, education, and previous roles is not available in the provided data. His leadership is pivotal in guiding the company's strategic direction and operational execution within the agricultural biotechnology sector.

Historial: Due to limited information, specific achievements, strategic decisions, and company milestones under Gang Chen's leadership cannot be detailed. His role involves overseeing the production, marketing, and distribution of bacteria-based products for livestock feed and crop cultivation.

Información del mercado OTC de CDBT

The OTC Other tier represents the lowest tier of the OTC market, indicating that China Dasheng Biotechnology Company may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited information available to investors, and the trading of their securities can be highly speculative. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements, leading to increased risks for investors.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Given that China Dasheng Biotechnology Company trades on the OTC Other market, liquidity is likely to be limited. This typically translates to lower trading volumes and wider bid-ask spreads, making it potentially difficult for investors to buy or sell shares without significantly affecting the price. The limited liquidity can increase volatility and the risk of substantial price fluctuations.
Factores de riesgo OTC:
  • Limited financial disclosure due to OTC Other listing.
  • Lower liquidity and wider bid-ask spreads.
  • Higher price volatility compared to exchange-listed stocks.
  • Potential for delisting or trading suspension due to non-compliance.
  • Increased risk of fraud or manipulation due to less regulatory oversight.
Lista de verificación de diligencia debida:
  • Verify the company's financial statements and audit reports.
  • Assess the company's business operations and revenue streams.
  • Investigate the background and experience of the company's management team.
  • Review the company's legal and regulatory filings.
  • Evaluate the company's competitive position and market share.
  • Determine the level of trading volume and liquidity.
  • Consult with a financial advisor to assess the risks and potential rewards.
Señales de legitimidad:
  • Operational business with products and services in the agricultural sector.
  • Presence in the Chinese market with a focus on bacteria-based additives.
  • Existence of a management team and employees.
  • Company history dating back to its initial incorporation as Max Nutrition, Inc.

Acciones de China Dasheng Biotechnology Company: Preguntas Clave Respondidas

¿Cuáles son los factores clave para evaluar CDBT?

China Dasheng Biotechnology Company (CDBT) actualmente tiene una puntuación IA de 38/100, indicando puntuación baja. Fortaleza clave: Specialized in bacteria-based agricultural additives.. Riesgo principal a monitorear: Potential: Limited financial disclosure due to OTC listing.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de CDBT?

CDBT actualmente puntúa 38/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de CDBT?

Los precios de CDBT se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre CDBT?

La cobertura de analistas para CDBT incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en CDBT?

Las categorías de riesgo para CDBT incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Limited financial disclosure due to OTC listing.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de CDBT?

La relación P/E para CDBT compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está CDBT sobrevalorada o infravalorada?

Determinar si China Dasheng Biotechnology Company (CDBT) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de CDBT?

China Dasheng Biotechnology Company (CDBT) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • Limited information available due to OTC listing and disclosure status.
  • AI analysis pending, which may provide further insights.
Fuentes de datos

Popular Stocks